Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Executive Summary
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich
You may also be interested in...
EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche
Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said
EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche
Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said
Enbrel Once-Weekly Dosing Will Help “Neutralize” Humira Advantage – Amgen
Amgen hopes a once-weekly dosing regimen for Enbrel will help offset Humira's biweekly dosing advantage, Exec VP-Global Communications Operations George Morrow says